cGMP MANUFACTURING FOR VIRAL VACCINES
Advaxia offers state-of-the-art facilities and tools for production at every scale.
At Advaxia, we recognize that vaccine manufacturing under cGMP conditions requires careful adherence to regulatory guidelines, from pre-GMP all the way to production and on-site delivery for clinical trials. Because the final product will be used on humans, it is crucial to ensure that every dose is free of contaminants and of the highest possible purity.
That’s why we have spent the past ten years perfecting a wide array of vaccine production pipelines, in alignment with the latest technology enhancements, as well as with the guidelines set forth by regulatory agencies around the globe.
Our major strengths in cGMP vaccine manufacturing include all the following:
We uphold rigorous product quality standards through a wide variety of interrelated approaches, from the design of our facility, to the selection of state-of-the-art laboratory equipment, to the choice of raw materials for every pilot batch and GMP production run. Moreover, we maintain a proactive and vigilant self-improvement posture, relentlessly seeking opportunities to further improve our processes and operations, personnel training and qualification standards, and regulatory compliance.